about
Reversal agents for NOACs: Connecting the dotsManagement of bleeding in patients treated with direct oral anticoagulantsAnticoagulation Reversal and Treatment Strategies in Major Bleeding: Update 2016Dabigatran approaching the realm of heparin-induced thrombocytopeniaManagement of antithrombotic therapy during cardiac implantable device surgeryDirect-Acting Oral Anticoagulants: Practical Considerations for Emergency Medicine PhysiciansHow we treat bleeding associated with direct oral anticoagulantsEfficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulationNon-Vitamin K Oral Anticoagulants in Stroke Patients: Practical IssuesEdoxaban in venous thromboembolism and stroke prevention: an appraisalReversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumabEmerging Tools for Stroke Prevention in Atrial FibrillationChallenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A ReviewManagement of Venous Thromboembolism: Recent Advances in Oral Anticoagulation TherapyCurrent Clinical Trials on the Use of Direct Oral Anticoagulants in the Pediatric PopulationHow to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillationPerioperative atrial fibrillation: a systematic review of evolving therapeutic options in pharmacologic and procedural managementNovel antidotes for target specific oral anticoagulantsPostoperative atrial fibrillation in patients undergoing non-cardiac non-thoracic surgery: A practical approach for the hospitalistThe European guideline on management of major bleeding and coagulopathy following trauma: fourth editionSpotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatranNon-vitamin K antagonist oral anticoagulants and antiphospholipid syndromeThe critical care management of spontaneous intracranial hemorrhage: a contemporary reviewMinimizing bleeding risk in patients receiving direct oral anticoagulants for stroke preventionDOACs - advances and limitations in real worldPeriprocedural Management of Non-Vitamin K Oral Anticoagulants in Chronic Kidney Disease: A Review of Existing Heterogeneity and Contemporary EvidenceBlood thinners and gastrointestinal endoscopyNonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversalReversal of direct oral anticoagulants in hemophilia treatment: ASH meeting 2015Antithrombotic management in patients with percutaneous coronary intervention requiring oral anticoagulationIntracerebral Hemorrhage: Perihemorrhagic Edema and Secondary Hematoma Expansion: From Bench Work to Ongoing ControversiesChoosing Non-Vitamin K Antagonist Oral Anticoagulants: Practical Considerations We Need to KnowPreclinical and clinical data for factor Xa and "universal" reversal agentsGuidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatmentPre-analytical issues in the haemostasis laboratory: guidance for the clinical laboratoriesPreclinical and Clinical Data for Factor Xa and "Universal" Reversal Agents.A Review of the Key Clinical Trials of 2015: Results and ImplicationsPerioperative Management of Direct Oral Anticoagulants (DOACs): A Systemic ReviewEvaluating the benefits of home-based management of atrial fibrillation: current perspectivesIdarucizumab
P2860
Q26740248-9F09F0F8-43AC-4609-A6B9-32B5AB5812EBQ26740258-26C2C1B1-7889-413E-BDE0-C566234DEED8Q26743727-985A4845-EF9B-4573-8351-C3537127FFF1Q26744261-278734AA-9E6E-4BE7-904D-EF93066EF9DEQ26746160-227BA7FF-6C78-45CC-B3A1-B1E4ED472918Q26746917-815A72E0-8122-4D90-AA52-19BA6A22778AQ26748343-4D0A262F-8A44-410B-B5E5-1EADC7ECFD60Q26749141-DFA799D2-317A-4788-A10E-3852884B95BBQ26750767-A79DE9C5-5177-4906-9FD3-AB91F545DCA6Q26751263-699D71DA-A9CD-4CCB-BD75-4ED5A9BB960AQ26764882-0B0A619E-1D27-420B-8D01-320BC3F0EC82Q26765023-9F6A8FCA-C271-49E3-B1D8-4F289F7E2FBEQ26765949-BFB8166F-F1C2-47C0-9522-D7C4595481A1Q26766303-6B0B4887-6010-4C0A-9F8A-1320500950D7Q26770402-AB92D171-7558-409C-84DB-2EDDDA322B0BQ26776413-85CD9DB8-26AC-482E-A8EE-F6A7985540E7Q26781769-B9467834-BBA3-4251-B3A8-16E795D0E767Q26784125-C213319B-FA80-45E6-8FFA-CCC759C489C8Q26785568-77AA3ED4-3F9D-47DD-81F5-A343F27DCE7DQ27339343-CBF81E1D-3A90-4732-BC31-E205E5783968Q28066262-BED7462A-43BD-4199-BBA2-FA8205F727F9Q28067420-DEFAAE9D-C2C6-4065-AB45-41E7C6B8762CQ28067962-F35E238F-0F51-43FA-944B-55EEAE43E3ABQ28069809-0F57150A-9F1A-4441-ABEE-7F629F4700B1Q28070132-7C8543B6-768A-4D45-B5AF-1A9B98028C48Q28071393-D1543FBB-8650-4922-BC68-DEBA18DBB5B6Q28071595-44545218-7B89-4724-A940-4E52C21FDFBBQ28071657-16883494-ECD5-40DA-9A1C-47B0D4DCC0CFQ28072261-A6BC3F60-5201-4542-88CE-CB20A477A065Q28072522-49E7FE76-E3A8-4EFA-B381-92CEA0733AF3Q28073307-BFB856E0-8008-40E5-A737-081BC562FBECQ28074445-E8C2AC44-C157-4081-A5F9-C231A4D94788Q28075637-D67F5131-10A5-4BE3-8026-1D8031FB52A3Q28076077-AA0A1833-8B1B-4525-8A4D-1EE5585ED11DQ28076774-BCD157D3-48A9-4F2C-9FCC-4F9424ACED25Q28076902-13045C60-E219-4FCE-B7FA-525A2813ECDEQ28077170-6DDAEA88-C22F-4BA6-80C6-D48C5148899DQ28078177-39D31896-5424-4170-8CD6-419A40B00DAEQ28079137-40FF3BAC-4AAC-4A47-B185-DE556D0AD9EDQ28079302-4BD4465F-E697-4E2D-86A5-63BC76F68B01
P2860
description
2015 nî lūn-bûn
@nan
2015 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Idarucizumab for Dabigatran Reversal
@ast
Idarucizumab for Dabigatran Reversal
@en
Idarucizumab for Dabigatran Reversal
@nl
type
label
Idarucizumab for Dabigatran Reversal
@ast
Idarucizumab for Dabigatran Reversal
@en
Idarucizumab for Dabigatran Reversal
@nl
prefLabel
Idarucizumab for Dabigatran Reversal
@ast
Idarucizumab for Dabigatran Reversal
@en
Idarucizumab for Dabigatran Reversal
@nl
P2093
P3181
P356
P1476
Idarucizumab for Dabigatran Reversal
@en
P2093
Bushi Wang
Chak-Wah Kam
Charles V Pollack
Elaine M Hylek
Frank W Sellke
Jeffrey I Weitz
Jerrold H Levy
Joachim Stangier
Jörg Kreuzer
Menno V Huisman
P304
P3181
P356
10.1056/NEJMOA1502000
P407
P577
2015-08-06T00:00:00Z